MAP Pharma (MAPP) Misses Q4 Views by 2c
- Wall St. set for lower open as investors seek safety
- Amid Concerns, Deutsche Bank (DB) co-CEO Says it Remains 'Absolutely Rock-Solid'
- Coca Cola (KO) Tops Q4 EPS by 1c
- A Michael Bloomberg Presidential Bid Would Likely Give GOP a Win Over Hilary Clinton
- Global stocks hit the rocks after Asian markets slump
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q4 loss of $0.46, 2 cents worse than the analyst estimate of ($0.44).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Entegris (ENTG) Tops Q3 EPS by 4c; Approves $100M Common Stock Buyback
- Steris (STE) Tops Q3 EPS by 4c
- Centene (CNC) Tops Q4 EPS by 5c, Offers FY16 Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!